Venus Concept (VERO) 10-Q 17 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 13, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Trading Symbol	VERO
Entity Registrant Name	Venus Concept Inc.
Entity Central Index Key	0001409269
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-38238
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1681204
Entity Address, Address Line One	235 Yorkland Blvd.
Entity Address, Address Line Two	Suite 900
Entity Address, City or Town	Toronto
Entity Address, Postal Zip Code	M2J 4Y8
Entity Address, State or Province	ON
City Area Code	877
Local Phone Number	848-8430
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		54,069,630

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 26,992	$ 34,297
Restricted cash	83	83
Accounts receivable, net of allowance of $17,694 and $18,490 as of March 31, 2021, and December 31, 2020	51,070	52,764
Inventories	17,985	17,759
Prepaid expenses	2,131	2,240
Advances to suppliers	4,004	2,587
Other current assets	4,410	5,674
Total current assets	106,675	115,404
LONG-TERM ASSETS:
Long-term receivables	19,296	21,148
Deferred tax assets	964	884
Severance pay funds	680	685
Property and equipment, net	3,132	3,539
Intangible assets	18,010	18,865
Total long-term assets	42,082	45,121
TOTAL ASSETS	148,757	160,525
CURRENT LIABILITIES:
Trade payables	6,143	6,322
Accrued expenses and other current liabilities	16,330	20,253
Taxes payable	1,376	1,132
Unearned interest income	2,444	1,950
Warranty accrual	1,222	1,106
Deferred revenues	1,616	1,752
Total current liabilities	29,131	32,515
LONG-TERM LIABILITIES:
Long-term debt	75,940	75,491
Government assistance loans	4,151	4,110
Taxes payable	478	478
Accrued severance pay	782	755
Deferred tax liabilities	574	811
Unearned interest income	1,034	1,778
Warranty accrual	471	533
Other long-term liabilities	247	293
Total long-term liabilities	83,677	84,249
TOTAL LIABILITIES	112,808	116,764
Commitments and Contingencies (Note 8)
STOCKHOLDERS’ EQUITY (Note 1):
Common Stock, $0.0001 par value: 300,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 54,069,630 and 53,551,126 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	26	26
Additional paid-in capital (Note 1)	203,221	201,598
Accumulated deficit	(166,651)	(157,392)
TOTAL STOCKHOLDERS’ EQUITY	36,596	44,232
Non-controlling interests	(647)	(471)
Total equity	35,949	43,761
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 148,757	$ 160,525

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 17,694	$ 18,490
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	54,069,630	53,551,126
Common stock, shares outstanding	54,069,630	53,551,126

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 22,597	$ 14,508
Cost of goods sold	7,363	5,228
Gross profit	15,234	9,280
Operating expenses:
Selling and marketing	7,854	8,611
General and administrative	12,165	14,176
Research and development	2,051	2,624
Goodwill impairment		27,450
Total operating expenses	22,070	52,861
Loss from operations	(6,836)	(43,581)
Other expenses:
Foreign exchange loss	714	4,279
Finance expenses	1,885	2,254
Loss before income taxes	(9,435)	(50,114)
Income tax expense		589
Net loss	(9,435)	(50,703)
Loss attributable to stockholders of the Company	(9,259)	(50,190)
Loss attributable to non-controlling interest	$ (176)	$ (513)
Net loss per share:
Basic	$ (0.17)	$ (1.68)
Diluted	$ (0.17)	$ (1.68)
Weighted-average number of shares used in per share calculation:
Basic	53,744	29,812
Diluted	53,744	29,812
Leases
Revenue	$ 8,537	$ 6,813
Cost of goods sold	1,770	1,452
Products and Services
Revenue	14,060	7,695
Cost of goods sold	$ 5,593	$ 3,776

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (9,435)	$ (50,703)
Loss attributable to stockholders of the Company	(9,259)	(50,190)
Loss attributable to non-controlling interest	(176)	(513)
Comprehensive loss	$ (9,435)	$ (50,703)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Series A Preferred Shares	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Non-controlling Interest
Beginning balance, value at Dec. 31, 2019	$ 76,678		$ 24	$ 149,840	$ (75,686)	$ 2,500
Beginning balance, shares at Dec. 31, 2019			28,686,116
2020 Private Placement shares, net of costs	12,115			12,115
2020 Private Placement shares, net of costs, shares		660,000	2,300,000
2020 Private Placement Warrants, net of costs	4,621			4,621
Beneficial conversion feature	3,564			3,564
Dividends from subsidiaries	(218)					(218)
Net loss - the Company	(50,190)				(50,190)
Net loss - non-controlling interest	(513)					(513)
Stock-based compensation	517			517
Ending balance, value at Mar. 31, 2020	46,574		$ 24	170,657	(125,876)	1,769
Ending balance, shares at Mar. 31, 2020		660,000	32,194,285
Issuance of common stock, shares			1,208,169
Beginning balance, value at Dec. 31, 2020	43,761		$ 26	201,598	(157,392)	(471)
Beginning balance, shares at Dec. 31, 2020			53,551,126
December 2020 Public Offering warrants exercise	903			903
December 2020 Public Offering warrants exercise, shares			361,200
Options exercised	$ 212			212
Options exercised, shares	157,304		157,304
Net loss - the Company	$ (9,259)				(9,259)
Net loss - non-controlling interest	(176)					(176)
Stock-based compensation	508			508
Ending balance, value at Mar. 31, 2021	$ 35,949		$ 26	$ 203,221	$ (166,651)	$ (647)
Ending balance, shares at Mar. 31, 2021			54,069,630

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$ (9,435)	$ (50,703)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill impairment			27,450
Depreciation and amortization		1,304	1,245
Stock-based compensation		508	517
Provision for bad debt		1,106	1,547	$ 15,212
Provision for inventory obsolescence		252	324
Finance expenses and accretion		489	2,032
Deferred tax (recovery) expense		(317)	281
Change in fair value of earn-out liability			179
Loss on disposal of property and equipment		13	29
Changes in operating assets and liabilities:
Accounts receivable short-term and long-term		2,448	10,194
Inventories		(478)	(522)
Prepaid expenses		109	(29)
Other current assets		(153)	381
Other long-term assets		(9)	5
Trade payables		(178)	(193)
Accrued expenses and other current liabilities		(3,554)	(6,960)
Severance pay funds		5	52
Unearned interest income		(249)	(973)
Other long-term liabilities		(81)	(261)
Net cash used in operating activities		(8,220)	(15,405)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(53)	(61)
Net cash used in investing activities		(53)	(61)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercises of 2020 December Public Offering Warrants		903
Payment of earn-out liability		(147)	(77)
Drawdown of line-of-credit			423
Proceeds from 2020 Private Placement, net of costs of $1,950	$ 20,300		20,300
Dividends from subsidiaries paid to non-controlling interest			(218)
Proceeds from exercise of options		212
Net cash provided by financing activities		968	20,428
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH		(7,305)	4,962
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period		34,380	15,749	15,749
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$ 20,711	27,075	20,711	$ 34,380
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes		73	329
Cash paid for interest		$ 1,731	$ 104

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Private Placement
Stock,issuance costs	$ 1,950

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Venus Concept Inc. is a global medical technology company that develops, commercializes, and sells minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The Company’s systems have been designed on cost-effective, proprietary and flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company was incorporated in the state of Delaware on November 22, 2002. In these notes to the condensed consolidated financial statements, the “Company” and “Venus Concept”, refer to Venus Concept Inc. and its subsidiaries on a consolidated basis. Going Concern The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future, and, as such, the unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. The Company has had recurring net operating losses and negative cash flows from operations. As of March 31, 2021 and December 31, 2020, the Company had an accumulated deficit of $166,651 and $157,392, respectively. The Company was in compliance with all required covenants as of March 31, 2021 and December 31, 2020. The Company’s recurring losses from operations and negative cash flows raise substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date that the unaudited condensed consolidated financial statements are issued. In addition, the coronavirus pandemic (“COVID-19” or “pandemic”) has had a significant negative impact on the Company’s unaudited condensed consolidated financial statements as of March 31, 2021 and for the three months then ended, and management expects the pandemic to continue to have a negative impact in the foreseeable future, the extent of which is uncertain and largely subject to whether the severity of the pandemic worsens, or duration lengthens. In the event that the COVID-19 pandemic and the economic disruptions it has caused continue for an extended period of time, the Company cannot assure that it will remain in compliance with the financial covenants in its credit facilities. In order to continue its operations, the Company must achieve profitable operations and/or obtain additional equity or debt financing. Until the Company achieves profitability, management plans to fund its operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock. On December 22, 2020, the Company issued and sold to the investors 11,250,000 shares of its common stock (“December 2020 Public Offering”), par value $0.0001 per share, at a combined offering price to the public of $2.00 per share and warrants (“December 2020 Public Offering Warrants”) to purchase up to 5,625,000 shares of common stock with an exercise price of $2.50 per share. The December 2020 Public Offering Warrants have a five-year In February 2021, several investors exercised an aggregate of 361,200 December 2020 Public Offering Warrants at the exercise price of $2.50 per share. The total proceeds received by the Company from the December 2020 Public Offering Warrants exercises were $903. Given the COVID-19 pandemic, the Company cannot anticipate the extent to which the current economic turmoil and financial market conditions will continue to adversely impact the Company’s business and the Company may need additional capital to fund its future operations and to access the capital markets sooner than planned. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, it may be compelled to reduce the scope of its operations and planned capital expenditures or sell certain assets, including intellectual property assets. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the uncertainty. Such adjustments could be material.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Venus Concept Inc. have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2021. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. The preparation of these unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 intangible and long-lived assets Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not equal the total amount reported in thousands due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Accounting Policies The accounting policies the Company follows are set forth in the Company’s audited consolidated financial statements for fiscal year 2020. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. JOBS Act Accounting Election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Risks and Uncertainties The Company has considered the impact of COVID-19 on its condensed consolidated financial statements. COVID-19 has had a significant negative impact on the Company’s unaudited condensed consolidated financial statements as of March 31, 2021 and for the three months then ended, and management expects the pandemic to continue to have a negative impact into the foreseeable future, the extent of which is uncertain and largely subject to whether the severity of the pandemic worsens, or duration lengthens. These impacts could include, but may not be limited to, risks and uncertainties related to the ability of the Company’s sales and marketing personnel and distributors to access the Company’s customer base, disruptions to the Company’s global supply chain, reduced demand and/or suspension of operations by the Company’s subscription customers which could impact their ability to make monthly payments, or deferral of aesthetic or hair restoration procedures which would impact the Company’s revenues. may subject the Company to future risk of material intangible and long-lived assets impairments, increased reserves for uncollectible accounts, and adjustments for inventory and market volatility for items subject to fair value measurements. Besides COVID-19, the Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company’s products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals. If the Company fails to adhere to the United States Food and Drug Administration’s (the “FDA”) Quality System Regulation, or regulations in countries other than the United States, the FDA or other regulators may withdraw its market clearances or take other action. The Company relies on suppliers to manufacture some of the components used in its products. The Company’s suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA’s Quality System Regulation, making errors in manufacturing or losing access to critical services and components, any of which could delay or impede the Company’s ability to meet demand for its products. The Company has borrowings with interest rates that are subject to fluctuations as charged by the lender. The Company does not use derivative financial instruments to mitigate the exposure to interest rate risk. The Company’s objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash used in operating activities to meet its requirements. As of March 31, 2021 and December 31, 2020, the most significant financial liabilities are trade payables, accrued expenses and other current liabilities and long-term debt. Recently Issued Accounting Standards Not Yet Adopted In April 2020, Financial Accounting Standards Board (the “FASB”) issued a Staff Question-and-Answer Document (Q&A): ASC Topic 842 and ASC Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic, that focuses on the application of the lease guidance for lease concessions related solely to the effects of COVID-19. The FASB issued the guidelines to reduce the burden and complexity for companies to account for such lease concessions (e.g., rent abatements or other economic incentives) under current lease accounting rules due to COVID-19 by providing certain practical expedients that can be used. This guidance can be applied immediately. The Company anticipates that the adoption of the guidance will not have a material impact on the Company’s unaudited condensed consolidated financial statements. In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04 - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASC Topic 848). This authoritative guidance provides optional relief for companies preparing for the discontinuation of interest rates such as LIBOR, which is expected to be phased out at the end of calendar 2021, and applies to lease contracts, hedging instruments, held-to-maturity debt securities and debt arrangements that have LIBOR as the benchmark rate. This guidance can be applied for a limited time, as of the beginning of the interim period that includes March 12, 2020 or any date thereafter, through December 31, 2022. The guidance may no longer be applied after December 31, 2022. In January 2021, the FASB issued authoritative guidance that makes amendments to the new rules on accounting for reference rate reform. The amendments clarify that all derivative instruments affected by the changes to interest rates used for discounting, margining or contract price alignment, regardless of whether they reference LIBOR, or another rate expected to be discontinued as a result of reference rate reform, an entity may apply certain practical expedients in ASC Topic 848. The Company is currently assessing the impact of applying this guidance as well as when to adopt this guidance. In February 2020, the FASB issued authoritative guidance (ASU 2020-02 – Financial Instruments – Credit Losses (Topic 326) and Leases (Topic 842)) that amends and clarifies Topic 326 and Topic 842. For Topic 326, the codification was updated to include the SEC staff interpretations associated with registrants engaged in lending activities. ASC Topic 326 is effective for annual periods beginning after January 1, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of applying this guidance on its financial instruments, such as accounts receivable. In December 2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, an authoritative guidance that simplifies the accounting for income taxes by removing certain exceptions and making simplifications in other areas. It is effective from the first quarter of fiscal year 2022, with early adoption permitted in any interim period. If adopted early, the Company must adopt all the amendments in the same period. The amendments have differing adoption methods including retrospectively, prospectively and/or modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, depending on the specific change. The Company is currently evaluating the impact of applying this guidance and believes that it has transactions that may fall under the scope of this guidance.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Share	3. NET LOSS PER SHARE Net Loss Per Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock warrants and stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): Three Months Ended March 31 2021 2020 Numerator: Net loss $ (9,435 ) $ (50,703 ) Net loss allocated to stockholders of the Company $ (9,259 ) $ (50,190 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share, basic and diluted 53,744 29,812 Net loss per share: Basic and diluted $ (0.17 ) $ (1.68 ) Due to the net loss, all the outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would have been antidilutive : March 31, 2021 March 31, 2020 Options to purchase common stock 2,532,184 2,730,791 Preferred stock - 660,000 Warrants for common stock 15,928,867 10,665,067 Total potential dilutive shares 18,461,051 14,055,858

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. FAIR Financial assets and financial liabilities are initially recognized at fair value when the Company becomes a party to the contractual provision of the financial instrument. Subsequently, all financial instruments are measured at amortized cost using the effective interest method. The financial instruments of the Company consist of cash and cash equivalents, restricted cash, accounts receivable, long-term receivables, lines of credit, trade payables, government assistance loans, accrued expenses and other current liabilities, earn-out liability, other long-term liabilities and long-term debt. In view of their nature, the fair value of these financial instruments approximates their carrying amounts. The Company measures the fair value of its financial assets and liabilities using the fair value hierarchy. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level - Quoted prices in active markets for identical assets or liabilities. Level - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The Company classifies its restricted cash within Level 1. Guaranteed investment certificates are classified within Level 2 as it uses alternative pricing sources and models utilizing market observable inputs. Contingent earn-out consideration was classified within Level 3. The following tables set forth the fair value of the Company’s Level 1, Level 2 and Level 3 financial assets and liabilities within the fair value hierarchy: Fair Value Measurements as of March 31, 2021 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates (GIC) $ — $ 65 $ — $ 65 Restricted cash 83 — — 83 Total assets $ 83 $ 65 $ — $ 148 Fair Value Measurements as of December 31, 2020 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates (GIC) $ — $ 64 $ — $ 64 Restricted cash 83 — — 83 Total assets $ 83 $ 64 $ — $ 147 Liabilities Contingent earn-out consideration — — 147 147 Total liabilities $ — $ — $ 147 $ 147 The earn-out liability was measured using discounted cash flow techniques, with the expected cash outflows estimated based on the probability of assessment of the acquired business achieving the revenue metrics required for payment. Expected future revenues of the acquired business and the associated estimate of probability are not observable inputs. The payments due are based on point in time measurements of the metrics quarterly for two years from the acquisition date. The following table provides a roll forward of the aggregate fair values of the earn-out liability for the three months ended March 31 Balance as of January 1, 2020 $ 655 Payments (799 ) Change in value 291 Balance as of December 31, 2020 147 Payments (147 ) Change in value - Balance as of March 31, 2021 $ -

Accounts Receivable

Accounts Receivable	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Accounts Receivable	5. ACCOUNTS RECEIVABLE The Company’s products may be sold under subscription agreements with title passing to the customer at the end of the lease term, which is generally 36 months. These arrangements are considered to be sales-type leases, where the present value of all cash flows to be received within the arrangement is recognized upon shipment to the customer as lease revenue. A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset on the Company's unaudited condensed consolidated balance sheets. The Company's financing receivables, consisting of sales-type leases, totaled $45,904 and $49,096 as of March 31, 2021 and December 31, 2020, respectively, and are included in accounts receivable and long-term receivables on the unaudited condensed consolidated balance sheets. The Company evaluates the credit quality of an obligor at lease inception and monitors credit quality over the term of the underlying transactions. The Company performed an assessment of the allowance for doubtful accounts as of March 31, 2021 and December 31, 2020. Based upon such assessment, the Company recorded an allowance for doubtful accounts totaling $17,694 and $18,490 as of March 31, 2021 and December 31, 2020, respectively. A summary of the Company’s accounts receivables is presented below: March 31, 2021 December 31, 2020 Gross accounts receivable $ 88,060 $ 92,402 Unearned income (3,478 ) (3,728 ) Allowance for doubtful accounts (17,694 ) (18,490 ) $ 66,888 $ 70,184 Reported as: Current trade receivables $ 51,070 $ 52,764 Current unearned interest income (2,444 ) (1,950 ) Long-term trade receivables 19,296 21,148 Long-term unearned interest income (1,034 ) (1,778 ) $ 66,888 $ 70,184 Current subscription agreements are reported as part of accounts receivable. The following are the contractual commitments, net of allowance for doubtful accounts, to be received by the Company over the next 5 years: March 31, Total 2021 2022 2023 2024 2025 Current financing receivables, net of allowance of $6,588 $ 26,609 $ 26,609 $ — $ — $ — $ — Long-term financing receivables, net of allowance of $4,629 19,295 — 14,380 4,837 78 — $ 45,904 $ 26,609 $ 14,380 $ 4,837 $ 78 $ — Accounts receivable do not bear interest and are typically not collateralized. The Company performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for doubtful accounts. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts receivable are presented net of an allowance for doubtful accounts. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Actual March 31, 2021 and December 31, 2020 The allowance for doubtful accounts consisted of the following activity: Balance as of January 1, 2020 $ 10,494 Write-offs (6,536 ) Provision 15,212 Sale of subsidiaries (680 ) Balance as of December 31, 2020 18,490 Write-offs (1,902 ) Provision 1,106 Balance as of March 31, 2021 17,694

Select Balance Sheet and Statem

Select Balance Sheet and Statement of Operations Information	3 Months Ended
	Mar. 31, 2021
Select Balance Sheet And Income Statement Information [Abstract]
Select Balance Sheet and Statement of Operations Information	6. SELECT BALANCE SHEET AND STATEMENT OF OPERATIONS INFORMATION Inventory Inventory March 31, 2021 December 31, 2020 Raw materials $ 1,908 $ 838 Work-in-progress 891 1,232 Finished goods 15,186 15,689 Total inventory $ 17,985 $ 17,759 Additions to inventory are primarily comprised of newly produced units and applicators, refurbishment cost from demonstration units and used equipment which were reacquired during the three months from upgraded sales. The Company expensed $6,020 in cost of goods sold in the three months ended March 31, 2021 March 31, 2020 The Company provides for excess and obsolete inventories when conditions indicate that the inventory cost is not recoverable due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. Inventory provisions are measured as the difference between the cost of inventory and net realizable value to establish a lower cost basis for the inventories. As of March 31, 2021 Property Property Useful Lives (in years) March 31, 2021 December 31, 2020 Lab equipment tooling and molds 4 - 10 $ 8,075 $ 8,053 Office furniture and equipment 6 - 10 1,716 1,760 Leasehold improvements up to 10 1,791 1,838 Computers and software 3 1,813 1,815 Vehicles 5 - 7 19 12 Total property and equipment 13,414 13,478 Less: Accumulated depreciation (10,282 ) (9,939 ) Total property and equipment, net $ 3,132 $ 3,539 Depreciation expense was $448 and $377 for the three months ended March 31, 2021 and 2020, respectively. Other Current Assets March 31, 2021 December 31, 2020 Government remittances (1) $ 1,049 $ 1,009 Consideration receivable from sales of subsidiaries 2,293 2,580 Deferred financing costs 381 1,063 Sundry assets and miscellaneous 687 1,022 Total other current assets $ 4,410 $ 5,674 (1) Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes. Accrued Expenses and Other Current Liabilities March 31, 2021 December 31, 2020 Payroll and related expense $ 1,513 $ 1,312 Accrued expenses 6,240 8,582 Commission accrual 2,265 2,827 Sales and consumption taxes 6,312 7,532 Total accrued expenses and other current liabilities $ 16,330 $ 20,253 Warranty Accrual The following table provides the details of the change in the Company’s warranty accrual: March 31, 2021 December 31, 2020 Balance as of the beginning of the period $ 1,639 $ 1,977 Warranties issued during the period 295 761 Warranty costs incurred during the period (241 ) (1,099 ) Balance at the end of the period $ 1,693 $ 1,639 Current 1,222 1,106 Long-term 471 533 Total $ 1,693 $ 1,639 Finance Expenses Three Months Ended March 31 2021 2020 Interest expense $ 1,138 $ 2,108 Accretion on long-term debt and amortization of fees 747 146 Total finance expenses $ 1,885 $ 2,254

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	7. INTANGIBLE ASSETS Intangible assets net of accumulated amortization and goodwill were as follows: At March 31, 2021 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (265 ) $ 1,135 Brand 2,500 (604 ) 1,896 Technology 16,900 (3,980 ) 12,920 Supplier agreement 3,000 (941 ) 2,059 Total intangible assets $ 23,800 $ (5,790 ) $ 18,010 At December 31, 2020 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (242 ) $ 1,158 Brand 2,500 (540 ) 1,960 Technology 16,900 (3,286 ) 13,614 Supplier agreement 3,000 (867 ) 2,133 Total intangible assets $ 23,800 $ (4,935 ) $ 18,865 Estimated amortization expense for the next five fiscal years and all years thereafter are as follows: April 1, 2021 to December 31, 2021 $ 2,618 2022 3,473 2023 3,473 2024 3,473 2025 3,004 Thereafter 1,969 Total $ 18,010

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. COMMITMENTS AND CONTINGENCIES Operating Leases The Company has various operating lease agreements, which expire on various dates. The Company recognizes rent expense on a straight-line basis over the non-cancellable lease period and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. When leases contain escalation clauses, rent abatements and/or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease period. Aggregate future minimum lease payments and purchase and service commitments with manufacturers and service providers as of March 31, 2021 are as follows: Office Lease Purchase and Service Commitments Total April 1, 2021 to March 31, 2022 $ 1,145 $ 8,287 $ 9,432 2023 718 — 718 2024 333 — 333 2025 210 — 210 2026 210 — 210 Thereafter 1,024 — 1,024 Total $ 3,640 $ 8,287 $ 11,927 The total rent expense for all operating leases for the three months ended March 31, 2021 and 2020 was $571 and $570, respectively. Commitments As of March 31, 2021 , the Company has non-cancellable purchase orders placed with its contract manufacturers in the amount of $6,585. In addition, as of March 31, 2021 , the Company had $7,019 of open purchase orders that can be cancelled with 90 days’ notice, except for a portion equal to 15% of the total amount representing the purchase of “long lead items”. On March 25, 2021, the Company entered into an endorsement agreement for the services of Venus Williams, four-time Olympic Gold Medalist, seven-time Grand Slam Champion and entrepreneur, pursuant to which Ms. Williams will act as a brand ambassador for Venus Bliss™. Legal Proceedings Purported Shareholder Class Actions Between May 23, 2018 and June 11, 2019, four putative shareholder class actions complaints were filed against Restoration Robotics, Inc., certain of its former officers and directors, certain of its venture capital investors, and the underwriters of the initial public offering (“IPO”). Two of these complaints, Wong v. Restoration Robotics, Inc., et al., No. 18CIV02609, and Li v. Restoration Robotics, Inc., et al., No. 19CIV08173 (together, the “State Actions”), were filed in the Superior Court of the State of California, County of San Mateo, and assert claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”). The other two complaints, Guerrini v. Restoration Robotics, Inc., et al., No. 5:18-cv-03712-EJD and Yzeiraj v. Restoration Robotics, Inc., et al., No. 5:18-cv-03883-BLF (together, the “Federal Actions”), were filed in the United States District Court for the Northern District of California and assert claims under Sections 11 and 15 of the Securities Act. The complaints all allege, among other things, that the Restoration Robotics’ Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with Restoration Robotics’ IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. The complaints seek unspecified monetary damages, other equitable relief and attorneys’ fees and costs. In the State Actions, Restoration Robotics, Inc., along with the other defendants, successfully demurred to the initial Wong complaint for failure to state a claim and secured a stay of both cases based on the forum selection clause contained in its Amended and Restated Certificate of Incorporation, which designates the federal district courts as the exclusive forums for claims arising under the Securities Act. However, on December 19, 2018, the Delaware Court of Chancery in Sciabacucchi v. Salzberg held that exclusive federal forum provisions are invalid under Delaware law. Based on this ruling, the San Mateo Superior Court lifted its stay of State Actions on December 10, 2019. On January 17, 2020, Plaintiffs in the State Actions filed a consolidated amended complaint for violations of federal securities laws, alleging again that, among other things, the Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with Restoration Robotics’ IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. The complaint seeks unspecified monetary damages, other equitable relief and attorneys’ fees and costs. On February 24, 2020, the Company demurred to the consolidated amended complaint for failure to state a claim. On March 18, 2020, the Delaware Supreme Court reversed the Chancery Court’s decision in Sciabacucchi v. Salzberg and held that exclusive federal forum provisions are valid under Delaware law. On March 30, 2020, the Company filed a renewed motion to dismiss based on its federal forum selection clause. A hearing on the Company’s demurrer and renewed motion to dismiss was held on June 12, 2020. On September 1, 2020, the court granted the renewed motion to dismiss based on the Company’s forum selection clause as to the Company and individual defendants, but not as to the venture capital and underwriter defendants. On September 22, 2020, the Court entered a judgement of dismissal as to the Company and the individual defendants. On November 23, 2020, plaintiff filed a notice of appeal of the Court’s order granting the renewed motion to dismiss. That appeal is pending. In the Federal Actions, which have been consolidated under the caption In re Restoration Robotics, Inc. Securities Litigation, Case No. 5:18-cv-03712-EJD, Lead Plaintiff Eduardo Guerrini filed his consolidated amended complaint for violations of federal securities laws on November 30, 2018. The consolidated amended complaint alleges again that, among other things, Restoration Robotics’ Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with the IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. On January 29, 2019, Restoration Robotics, Inc., along with certain of its former officers and directors, filed a motion to dismiss the consolidated amended complaint for failure to state a claim. On October 18, 2019, the District Court granted Restoration Robotics, Inc. motion to dismiss as to all but two allegedly false or misleading statements contained in the Company’s Prospectus. On December 9, 2019, the Company filed its answer to the consolidated amended complaint denying the falsity of these statements. On May 29, 2020, Lead Plaintiff filed a motion for class certification, which the Company elected not to oppose, and on July 29, 2020, the court certified a class of investors who purchased shares of the Company’s common stock pursuant or traceable to the Company’s IPO. On February 22, 2021, the District Court granted the parties’ joint stipulation to stay all pending deadlines on the basis that the parties had reached a settlement in principle for all claims in the Federal Actions. On April 22, 2021, Lead Plaintiff filed his unopposed motion for preliminary approval of settlement. A hearing on that motion is scheduled for May 27, 2021. In addition to the State and Federal Actions, on July 11, 2019, a verified shareholder derivative complaint was filed in the United States District Court for the Northern District of California, captioned Mason v. Rhodes, No. 5:19-cv-03997-NC. The complaint alleges that certain of Restoration Robotics’ former officers and directors breached their fiduciary duties, have been unjustly enriched and violated Section 14(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) in connection with the IPO and Restoration Robotics’ 2018 proxy statement. The complaint seeks unspecified damages, declaratory relief, other equitable relief and attorneys’ fees and costs. On August 21, 2019, the District Court granted the parties’ joint stipulation to stay the Mason action during the pendency of the Federal Actions. On March 16, 2021, the District Court granted the parties’ further stipulation to stay the Mason action during the pendency of the Federal Action, and the case remains stayed. Administrative Investigation Case The Company’s Chinese subsidiary, Venus Concept China, imports and sells registered medical devices and unregistered non-medical devices in the People’s Republic of China (“PRC”). One of its unregistered products has been the subject of inquiries from two district level branches of the State Administration for Market Regulation, Xuhui MSA and Huangpu MSA, as to whether the product was properly sold as a non-medical device. In January 2019, Venus Concept China applied to register a version of this non-medical device as a medical device with the National Medical Products Administration of PRC (“NMPA”). On June 12, 2019, Venus Concept China was informed that Xuhui MSA had opened an administrative investigation case related to whether the device is an unregistered medical device, as a result of a complaint that Xuhui MSA received from a former distributor of Venus Concept China. Huangpu MSA notified Venus Concept China that it would be suspending its separate investigation against Venus Concept China, pending the results of the Xuhui MSA investigation. The Company and Venus Concept China have voluntarily stopped sales in China of this product. On December 11, 2019, Xuhui MSA informed Venus Concept China that a determination had been made by the Shanghai Medical Products Administration that Versa’s IPL function should be administered as a Class II medical device. Xuhui MSA also suggested that Venus Concept China consider a voluntary recall of all Versa units sold in China. In late January 2020, Venus Concept China received a copy of the Shanghai Medical Products Administration’s determination that because of the intended uses for Versa’s IPL function comprise medical treatment functions such as “treatment of benign pigmented epidermis and skin lesions”, Versa’s IPL function should be administered as a Class II medical device. In April 2020, Venus Concept China received a determination from NMPA on its application for registering Versa’s IPL function as a medical device. NMPA has approved the registration of one applicator HR 650 for hair removal as a Class II medical device out of the four IPL applicators for which Venus Concept China had originally applied. The date of registration is April 15, 2020. Venus Concept China also submitted an explanation letter and a draft Corrective & Preventive Action Report plan to Xuhui MSA during a meeting with the local authority on April 23, 2020. On March 4, 2021, Xuhui MSA issued a written administrative penalty hearing notice (the “Notice”) to Venus Concept China. The Notice stated that Venus Concept China’s sale of Versa violated the relevant Chinese medical device administration regulation. As a result, Xuhui MSA proposed an administrative monetary penalty in the amount of approximately $150 or 976 Chinese Yuan (the “Penalty Amount”). On March 8, 2021, Venus Concept China gave written notice to Xuhui MSA that it accepted the penalty decision proposed by Xuhui MSA. On March 19, 2021, Xuhui MSA issued a written administrative penalty decision to Venus Concept China (the “Decision”), which affirmed the administrative penalty proposed by the Notice. On March 19, 2021, the same day the Decision was issued, Venus Concept China remitted the full Penalty Amount to Xuhui MSA. Acceptance of the payment of the Penalty Amount by Xuhui MSA resulted in the conclusion of its investigation case against Venus Concept China and settlement of this matter. This matter is now resolved and closed by Xuhui MSA. Further, the Company may from time to time continue to be involved in various legal proceedings of a character normally incident to the ordinary course of its business, which the Company does not deem to be material to its business and results of operations.

Main Street Term Loan

Main Street Term Loan	3 Months Ended
	Mar. 31, 2021
Main Street Term Loan
Debt Instrument [Line Items]
Main Street Term Loan/Madryn Long-term Debt and Convertible Notes	9. MAIN STREET TERM LOAN On December 8, 2020, the Company executed a loan and security agreement (the “MSLP Loan Agreement”), a promissory note (the “MSLP Note”), and related documents for a loan in the aggregate amount of $50,000 for which City National Bank of Florida (“CNB”) will serve as a lender pursuant to the Main Street Priority Loan Facility as established by the Board of Governors of the Federal Reserve System Section 13(3) of the Federal Reserve Act (the “MSLP Loan”). On December 9, 2020, the MSLP Loan had been funded and the transaction was closed. The MSLP Note has a term of five years and bears interest at a rate per annum equal to 30-day LIBOR plus 3%. On December 8, 2023 and December 8, 2024, the Company must make an annual payment of principal plus accrued but unpaid interest in an amount equal to fifteen percent ( 15% As of March 31, 2021 and December 31, 2020, the Company was in compliance with all required covenants. The scheduled payments on the outstanding borrowings as of March 31, 2021 are as follows: As of March 31, 2021 2021 $ - 2022 1,604 2023 9,339 2024 7,942 2025 38,416 Total $ 57,301

Madryn Long-term Debt and Conve

Madryn Long-term Debt and Convertible Notes	3 Months Ended
	Mar. 31, 2021
Madryn Long-term Debt and Convertible Notes
Debt Instrument [Line Items]
Main Street Term Loan/Madryn Long-term Debt and Convertible Notes	10. MADRYN LONG-TERM DEBT AND CONVERTIBLE NOTES Madryn Credit Agreement On December 9, 2020, contemporaneously with the MSLP Loan Agreement (Note 9), the Company, Venus Concept USA, Inc. (“Venus USA”), Venus Concept Canada Corp., Venus Concept Ltd., and the Madryn Noteholders (as defined below), entered into a Securities Exchange Agreement (the “Exchange Agreement”) dated as of December 8, 2020, pursuant to which the Company (i) repaid $42,500 aggregate principal amount owed under that certain credit agreement originally entered into on October 11, 2016 and amended from time to time, between Venus Concept Ltd., Madryn Health Partners, LP and certain of its affiliates (the “Madryn Credit Agreement”), and (ii) issued, to the Madryn Health Partners (Cayman Master), LP and Madryn Health Partners, LP (together the “Madryn Noteholders”) secured subordinated convertible notes in the aggregate principal amount of $26,695 (the “Notes”). The Madryn Credit Agreement was terminated effective December 9, 2020 upon the funding and closing of the MSLP Loan and the issuance of the Notes. The Notes will accrue interest at a rate of 8.0% per annum from the date of original issuance of the Notes to the third anniversary date of the original issuance and thereafter interest will accrue at a rate 6.0% per annum. Under certain circumstances, in the case of an event of default under the Notes, the then-applicable interest rate will increase by 4.0% per annum. Interest is payable quarterly in arrears on the last business day of each calendar quarter of each year after the original issuance date, beginning on December 31, 2020. The Notes will mature on December 9, 2025, unless earlier redeemed or converted. In connection with the Exchange Agreement, the Company also entered into, by and among the Company, Venus USA, Venus Concept Canada Corp., Venus Concept Ltd., and the Madryn Noteholders, (i) a Guaranty and Security Agreement dated as of December 9, 2020 (the “Madryn Security Agreement”), pursuant to which the Company agreed to grant Madryn a security interest, in substantially all of its assets, to secure the obligations under the Notes and (ii) a Subordination of Debt Agreement dated as of December 9, 2020 (the “CNB Subordination Agreement”). The security interests and liens granted to the Madryn Noteholders under the Madryn Security Agreement will terminate upon the earlier of (i) an assignment of the Notes (other than to an affiliate of the Madryn Noteholders) pursuant to the terms of the Exchange Agreement and (ii) the first date on which the outstanding principal amount of the Notes is less than $10,000. Obligations under the Notes are secured by substantially all of the assets of the Venus Concept Inc. and its subsidiaries party to the Madryn Security Agreement. The Company’s obligations under the Notes and the security interests and liens created by the Madryn Security Agreement are subordinated to the Company’s indebtedness owing to CNB (including, but not limited, pursuant to the MSLP Loan Agreement and the CNB Loan Agreement, (Note 11)) and any security interests and liens which secure such indebtedness owing to CNB. The Notes have a 5-year term and the interest rate on the convertible notes decreases to 6% on the third anniversary of the issuance. The Notes are convertible at any time into shares of the Company’s common stock, par value $0.0001 per share, calculated by dividing the outstanding principal amount of the Notes (and any accrued and unpaid interest under the Notes) by the initial conversion price of $3.25 per share. In connection with the Notes, the Company recognized interest expense of $527 during the three months ended March 31, 2021. The conversion feature, providing the Madryn Noteholders with a right to receive the Company’s shares upon conversion of the Notes, was qualified for a scope exception in ASC 815-10-15 and did not require bifurcation. The Notes also contained embedded redemption features that provided multiple redemption alternatives. Certain redemption features provided the Madryn Noteholders with a right to receive cash and a variable number of shares upon change of control and an event of default (as defined in the Notes). The Company evaluated redemption upon change of control and an event of default under ASC 815, Derivatives and Hedging, and determined that these two redemption features required bifurcation. These embedded derivatives were accounted for as liabilities at their estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the unaudited condensed consolidated statements of operations. The Company determined the likelihood of an event of default and change of control as remote as of March 31, 2021, and December 31, 2020, therefore a nominal value was allocated to the underlying embedded derivative liabilities as of March 31, 2021, and December 31, 2020. The scheduled payments on the outstanding borrowings as of March 31, 2021 are as follows: As of March 31, 2021 2021 $ 1,609 2022 2,136 2023 2,102 2024 1,606 2025 28,196 Total $ 35,649 For the three months ended March 31, 2021, the Company did not make any principal repayments.

Credit Facility

Credit Facility	3 Months Ended
	Mar. 31, 2021
Line Of Credit Facility [Abstract]
Credit Facility	11. The Company has an agreement with CNB pursuant to which CNB agreed to provide a revolving credit facility to the Company in the maximum principal amount of $10,000 to be used to finance working capital requirements (the “CNB Loan Agreement”). The CNB Loan Agreement contains various covenants that limit the Company’s ability to engage in specified types of transactions. Subject to limited exceptions, these covenants limit the Company’s ability, without CNB’s consent, to, among other things, sell, lease, transfer, exclusively license or dispose of the Company’s assets, incur, create or permit to exist additional indebtedness, or liens, to make dividends and certain other restricted payments, and to make certain changes to its management and/or ownership structure. The CNB Loan Agreement also contains a covenant requiring that a minimum of $23,000 in cash be held in a deposit account maintained with CNB for one year following the closing of the CNB Loan Agreement, and after the first anniversary of the CNB Loan Agreement, a minimum of $3,000 in cash must be held in a deposit account maintained with CNB. The Madryn Noteholders have agreed to hold $20,000 in cash in an escrow account at CNB, and pursuant to an escrow agreement, such cash will be released back to the Madryn Noteholders on the first anniversary of the CNB Loan Agreement. The Company is required to maintain $3,000 in cash in a deposit account maintained with CNB at all times during the term of the CNB Loan Agreement. In addition, the CNB Loan Agreement contains certain covenants that require the Company to achieve certain minimum account balances, or a minimum debt service coverage ratio and a maximum total liability to tangible net worth ratio. If the Company fails to comply with these covenants, it will result in a default and require the Company to repay all outstanding principal amounts and any accrued interest. In connection with the CNB Loan Agreement, a loan fee of $1,000 was paid in equal installments on January 25, February 25 and March 25, 2021. As of March 31, 2021 and December 31, 2020, the Company was in compliance with all required covenants. An event of default under this agreement would cause a default under the MSLP Loan (see Note 9).

Government Assistance Programs

Government Assistance Programs	3 Months Ended
	Mar. 31, 2021
Government Assistance Programs [Abstract]
Government Assistance Programs	12. GOVERNMENT ASSISTANCE PROGRAMS Venus Concept Inc. and Venus USA, received funding in the total amount of $4,048 in connection with two Small Business Loans under the federal Paycheck Protection Program provided in Section 7(a) of the Small Business Act of 1953, as amended by the Coronavirus Aid, Relief, and Economic Security Act, as amended from time to time (the “PPP”). Venus Concept Inc. entered the U.S. Small Business Administration Note dated as of April 21, 2020 in favor of CNB pursuant to which the Company borrowed $1,665 original principal amount, which was funded on April 29, 2020 (the “Venus Concept PPP Loan”). The Venus Concept PPP Loan bears interest at 1% per annum and matures in two years from the date of disbursement of funds under the loan. Interest and principal payments under the Venus Concept PPP Loan will be deferred for a period of six months. The Venus Concept PPP Loan contains certain covenants which, among other things, restrict the Company’s use of the proceeds of the PPP Loan to the payment of payroll costs, interest on mortgage obligations, rent obligations and utility expenses, require compliance with all other loans or other agreements with any creditor of the Company, to the extent that a default under any loan or other agreement would materially affect the Company’s ability to repay its PPP Loan and limit the Company’s ability to make certain changes to its ownership structure. Venus USA entered into a U.S. Small Business Administration Note dated as of April 15, 2020 in favor of CNB. Venus USA borrowed $2,383 original principal amount, which was funded on April 20, 2020 (the “Venus USA PPP Loan” and together with the Venus Concept PPP Loan, individually each a “PPP Loan” and collectively, the “PPP Loans”). The terms of the Venus USA PPP Loan are substantially similar to the terms of the Venus Concept PPP Loan. Under certain circumstances, all or a portion of the PPP Loans may be forgiven, however, there can be no assurance that any portion of the PPP Loans will be forgiven and that the Company would not be required to repay the PPP Loans in full. The Company has applied through CNB for partial forgiveness of Venus USA PPP Loan in the amount of $1,689 and the Venus Concept PPP Loan in the amount of $1,086. The Company recorded PPP Loans within the long-term liabilities in the unaudited condensed consolidated balance sheet. Under the CNB Loan Agreement and the MSLP Loan Agreement MSLP Loan Agreement The U.S. Small Business Administration (the “SBA”) has decided, in consultation with the Department of the Treasury, that it will review all loans in excess of $2,000 following the lender’s submission of the borrower’s loan forgiveness application. To the extent that the SBA’s audit determines that Venus USA was not entitled to the loan under the PPP, the loan may not be forgiven, an event of default would occur under the CNB Loan Agreement and the MSLP Loan Agreement As of March 31, 2021, the Company had $4,151 outstanding under the PPP Loans (4,110 as of December 31, 2020). Certain of the Company’s subsidiaries applied for government assistance programs and received government subsidies aggregating $1,117. The terms of these government assistance programs vary by jurisdiction. government subsidies received as a reduction to the associated wage costs in general and administrative expenses in the unaudited condensed consolidated statement of operations.

Common Stock Reserved For Issua

Common Stock Reserved For Issuance	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Common Stock Reserved For Issuance	13. COMMON STOCK RESERVED The Company is required to reserve and keep available out of its authorized but unissued shares of common stock a number of shares sufficient to affect the exercise of all options granted and available for grant under the incentive plans and warrants to purchase common stock. March 31, 2021 December 31, 2020 Outstanding common stock warrants 15,928,867 16,290,067 Outstanding stock options 5,899,296 4,433,392 Shares reserved for future option grants 781,227 262,622 Shares reserved for Lincoln Park 5,222,867 5,222,867 Shares reserved for Madryn Noteholders 8,213,880 8,213,880 Total common stock reserved for issuance 36,046,137 34,422,828

Stockholders Equity

Stockholders Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders Equity	14. STOCKHOLDERS EQUITY Common Stock The Company’s common stock confers upon its holders the following rights: • The right to participate and vote in the Company’s stockholder meetings, whether annual or special. Each share will entitle its holder, when attending and participating in the voting in person or via proxy, to one vote; • The right to a share in the distribution of dividends, whether in cash or in the form of bonus shares, the distribution of assets or any other distribution pro rata to the par value of the shares held by them; and • The right to a share in the distribution of the Company’s excess assets upon liquidation pro rata to the par value of the shares held by them. 2020 Private Placement Warrants In March 2020, the Company issued and sold to certain investors (collectively the “Investors”) warrants (the “2020 Private Placement Warrants”) to purchase up to 6,675,000 shares of common stock with an exercise price of $3.50 per share, along with the shares of common stock and preferred stock the Investors purchased (the “2020 Private Placement”). The 2020 Private Placement Warrants have a five-year Total net proceeds of $20,300 reduced by $3,564 of the beneficial conversion feature were allocated as follows: $8,063 to Series A Preferred Stock, $4,052 to shares of common stock and $4,621 to the 2020 Private Placement Warrants issued. Series A Preferred Stock and common stock issued in the 2020 Private Placement were recorded at par value of $0.0001 with the excess of par value recorded in APIC. December 2020 Public Offering Warrants and common stock As noted in Note 1 above, in December 2020, the Company issued and sold to the investors in the December 2020 Public Offering 11,250,000 shares of its common stock and warrants to purchase up to 5,625,000 shares of common stock with an exercise price of $2.50 per share. The December 2020 Public Offering Warrants have a five-year Total net proceeds of $20,476 were allocated as follows: $17,828 to shares of common stock and $2,648 to the December 2020 Public Offering Warrants issued. Common stock issued in the December 2020 Public Offering were recorded at par value of $0.0001 with the excess of par value recorded in APIC. In February 2021, several investors exercised an aggregate of 361,200 December 2020 Public Offering Warrants at the exercise price of $2.50 per share. The total proceeds received by the Company from the December 2020 Public Offering Warrants exercises were $903. 2010 Share Option Plan In November 2010, the Company’s Board of Directors (the “Board”) adopted a share option plan (the “2010 Share Option Plan”) pursuant to which shares of the Company’s common stock are reserved for issuance upon the exercise of options to be granted to directors, officers, employees and consultants of the Company. The 2010 Share Option Plan is administered by the Board, which designates the options and dates of grant. Options granted vest over a period determined by the Board, originally had a contractual life of seven years, which was extended to ten years 2019 The 2019 Incentive Award Plan (the “2019 Plan”) was originally established under the name Restoration Robotics, Inc., as the 2017 Incentive Award Plan. It was adopted by the Board on September 12, 2017 and approved by the Company’s stockholders on September 14, 2017. The 2017 Incentive Award Plan was amended, restated, and renamed as set forth above, and was approved by the Company’s stockholders on October 4, 2019. Under the 2019 Plan, 450,000 shares of common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, performance stock awards, performance stock unit awards, restricted stock awards, restricted stock unit awards and other stock-based awards, plus the number of shares remaining available for future awards under the 2019 Plan as of the date we completed our business combination with Venus Concept Ltd. and the business of Venus Concept Ltd. became the primary business of the Company (the “Merger”). As of March 31, 2021, there were 687,788 of shares of common stock available under the 2019 Plan (124,347 as of December 31, 2020). The 2019 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year from 2020 and ending in 2029 equal to the lesser of (A) four percent (4.00%) of the shares of stock outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by the Board. The Company recognized stock-based compensation for its employees and non-employees in the accompanying unaudited condensed consolidated statements of operations as follows: Three Months Ended March 31 2021 2020 Cost of sales $ 7 $ 6 Selling and marketing 217 192 General and administrative 264 299 Research and development 20 20 Total stock-based compensation $ 508 $ 517 Stock Options The fair value of each option is estimated at the date of grant using the Black-Scholes option pricing formula with the following assumptions : Three Months Ended March 31 2021 2020 Expected term (in years) 6.01 5.00-6.64 Risk-free interest rate 1.09 % 0.57-1.50 % Expected volatility 44.80 % 43.00 % Expected dividend rate 0 % 0 % Expected Term —The expected term represents management’s best estimate for the options to be exercised by option holders. Volatility —Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry that are considered to be comparable to the Company’s business over a period equivalent to the expected term of the stock-based awards. Risk-Free Interest Rate —The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the stock-based awards’ expected term. Dividend Rate —The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock in the foreseeable future Fair Value of Common Stock — Prior to the Merger, Venus Concept Ltd. used the price per share in its latest sale of securities as an estimate of the fair value of its ordinary shares. After the closing of the Merger, the fair value of the Company’s common stock is used to estimate the fair value of the stock-based awards at grant date. The following table summarizes stock option activity under the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price per Share, $ Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding – January 1, 2021 4,433,392 $ 4.59 6.20 $ 247 Options granted 1,857,000 2.37 - Options exercised (157,304 ) 2.39 157 Options forfeited/cancelled (233,792 ) 4.49 - Outstanding - March 31, 2021 5,899,296 $ 3.98 7.37 $ 502 Exercisable – March 31, 2021 2,532,184 $ 4.70 4.60 $ 493 Expected to vest – after March 31, 2021 3,367,112 $ 3.44 9.46 $ - The following tables summarize information about stock options outstanding and exercisable at March 31, 2021: Options Outstanding Options Exercisable Exercise Price Range Number Weighted average remaining contractual term (years) Weighted average Exercise Price Options exercisable Weighted average remaining contractual term (years) Weighted average Exercise Price $0.15 - $3.64 4,405,983 7.72 $ 2.81 1,498,108 4.00 $ 2.86 $4.26 - $7.95 1,437,306 6.34 6.78 991,451 5.44 6.54 $12.45 - $26.10 34,442 7.44 18.49 21,451 7.30 18.89 $27.00 - $33.00 12,998 3.60 27.99 12,962 3.59 27.98 $36.00 - $94.65 8,567 6.30 45.74 8,212 6.26 45.31 5,899,296 7.37 $ 3.98 2,532,184 4.60 $ 4.70 The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The total intrinsic value of options exercised were $157 and $nil for the three months ended March 31, 2021 and 2020, respectively. The weighted-average grant date fair value of options granted was $2.37 and $7.515 per share for the three months ended March 31, 2021 and 2020, respectively.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	15. INCOME TAXES The Company generated a loss and recognized $ nil A reconciliation of income tax expense is as follows: Three Months Ended March 31 2021 2020 Loss before income taxes $ (9,435 ) $ (50,114 ) Theoretical tax benefit at the statutory rate (21.0% in 2021, 24.1% in 2020) (1,981 ) (12,077 ) Differences in jurisdictional tax rates (354 ) (172 ) Losses utilization — (101 ) Valuation allowance 1,984 5,362 Non-deductible expenses 334 7,577 Other 17 — Total income tax expense — 589 Net loss $ (9,435 ) $ (50,703 ) Income tax benefit is recognized based on the actual income or loss incurred during the three months ended March 31, 2021 and 2020, respectively.

Segment and Geographic Informat

Segment and Geographic Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment and Geographic Information	16. SEGMENT AND GEOGRAPHIC INFORMATION Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. The Company has determined it operates in a single The Company does not assess the performance of individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues by geography and type. Revenue by geographic location, which is based on the product shipped to location, is summarized as follows: Three Months Ended March 31 2021 2020 United States $ 10,877 $ 5,640 International 11,720 8,868 Total revenue $ 22,597 $ 14,508 As of March 31 December 31 Revenue by type is a key indicator for providing management with an understanding of the Company’s financial performance, which is organized into four different categories: 1. 2. 3. 4. The following table presents revenue by type: Three Months Ended March 31 2021 2020 Lease revenue $ 8,537 $ 6,813 System revenue 9,810 3,498 Product revenue 3,055 2,717 Service revenue 1,195 1,480 Total revenue $ 22,597 $ 14,508

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	17. RELATED PARTY TRANSACTIONS All amounts were recorded at the exchange amount, which is the amount established and agreed to by the related parties. The following are transactions between the Company and its related parties: Distribution Agreements On January 1, 2018, the Company entered into a distribution agreement with Technicalbiomed Co., Ltd. (“TBC”), pursuant to which TBC will continue to distribute the Company’s products in Thailand. A senior officer of the Company is a 30.0% shareholder of TBC. For the three months ended March 31, 2021 and 2020, TBC purchased products in the amount of $15 and $49, respectively, under this distribution agreement. These sales are included in products and services revenue. In 2020, the Company made several strategic decisions to divest of underperforming direct sales offices and sold its share in several subsidiaries, including its 55.0% shareholding in Venus Concept Singapore Pte. Ltd (“Venus Singapore”) . On January 1, 2021, the Company entered into a distribution agreement with Venus Singapore , pursuant to which Venus Singapore will continue to distribute the Company’s products in Singapore. A senior officer of the Company is a 45.0% shareholder of Venus Singapore . For the three months ended March 31, 2021, Venus Singapore purchased products in the amount of $65 under the distribution agreement. These sales are included in products and services revenue.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Venus Concept Inc. have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2021. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. The preparation of these unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 intangible and long-lived assets Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not equal the total amount reported in thousands due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Accounting Policies The accounting policies the Company follows are set forth in the Company’s audited consolidated financial statements for fiscal year 2020. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K.
Jobs Act Accounting Election	JOBS Act Accounting Election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Risks and Uncertainties	Risks and Uncertainties The Company has considered the impact of COVID-19 on its condensed consolidated financial statements. COVID-19 has had a significant negative impact on the Company’s unaudited condensed consolidated financial statements as of March 31, 2021 and for the three months then ended, and management expects the pandemic to continue to have a negative impact into the foreseeable future, the extent of which is uncertain and largely subject to whether the severity of the pandemic worsens, or duration lengthens. These impacts could include, but may not be limited to, risks and uncertainties related to the ability of the Company’s sales and marketing personnel and distributors to access the Company’s customer base, disruptions to the Company’s global supply chain, reduced demand and/or suspension of operations by the Company’s subscription customers which could impact their ability to make monthly payments, or deferral of aesthetic or hair restoration procedures which would impact the Company’s revenues. may subject the Company to future risk of material intangible and long-lived assets impairments, increased reserves for uncollectible accounts, and adjustments for inventory and market volatility for items subject to fair value measurements. Besides COVID-19, the Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, rapid technological change, continued acceptance of the Company’s products, competition from substitute products and larger companies, protection of proprietary technology, strategic relationships and dependence on key individuals. If the Company fails to adhere to the United States Food and Drug Administration’s (the “FDA”) Quality System Regulation, or regulations in countries other than the United States, the FDA or other regulators may withdraw its market clearances or take other action. The Company relies on suppliers to manufacture some of the components used in its products. The Company’s suppliers may encounter supply interruptions or problems during manufacturing due to a variety of reasons, including failure to comply with applicable regulations, including the FDA’s Quality System Regulation, making errors in manufacturing or losing access to critical services and components, any of which could delay or impede the Company’s ability to meet demand for its products. The Company has borrowings with interest rates that are subject to fluctuations as charged by the lender. The Company does not use derivative financial instruments to mitigate the exposure to interest rate risk. The Company’s objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash used in operating activities to meet its requirements. As of March 31, 2021 and December 31, 2020, the most significant financial liabilities are trade payables, accrued expenses and other current liabilities and long-term debt.
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted In April 2020, Financial Accounting Standards Board (the “FASB”) issued a Staff Question-and-Answer Document (Q&A): ASC Topic 842 and ASC Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic, that focuses on the application of the lease guidance for lease concessions related solely to the effects of COVID-19. The FASB issued the guidelines to reduce the burden and complexity for companies to account for such lease concessions (e.g., rent abatements or other economic incentives) under current lease accounting rules due to COVID-19 by providing certain practical expedients that can be used. This guidance can be applied immediately. The Company anticipates that the adoption of the guidance will not have a material impact on the Company’s unaudited condensed consolidated financial statements. In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04 - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASC Topic 848). This authoritative guidance provides optional relief for companies preparing for the discontinuation of interest rates such as LIBOR, which is expected to be phased out at the end of calendar 2021, and applies to lease contracts, hedging instruments, held-to-maturity debt securities and debt arrangements that have LIBOR as the benchmark rate. This guidance can be applied for a limited time, as of the beginning of the interim period that includes March 12, 2020 or any date thereafter, through December 31, 2022. The guidance may no longer be applied after December 31, 2022. In January 2021, the FASB issued authoritative guidance that makes amendments to the new rules on accounting for reference rate reform. The amendments clarify that all derivative instruments affected by the changes to interest rates used for discounting, margining or contract price alignment, regardless of whether they reference LIBOR, or another rate expected to be discontinued as a result of reference rate reform, an entity may apply certain practical expedients in ASC Topic 848. The Company is currently assessing the impact of applying this guidance as well as when to adopt this guidance. In February 2020, the FASB issued authoritative guidance (ASU 2020-02 – Financial Instruments – Credit Losses (Topic 326) and Leases (Topic 842)) that amends and clarifies Topic 326 and Topic 842. For Topic 326, the codification was updated to include the SEC staff interpretations associated with registrants engaged in lending activities. ASC Topic 326 is effective for annual periods beginning after January 1, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of applying this guidance on its financial instruments, such as accounts receivable. In December 2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, an authoritative guidance that simplifies the accounting for income taxes by removing certain exceptions and making simplifications in other areas. It is effective from the first quarter of fiscal year 2022, with early adoption permitted in any interim period. If adopted early, the Company must adopt all the amendments in the same period. The amendments have differing adoption methods including retrospectively, prospectively and/or modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, depending on the specific change. The Company is currently evaluating the impact of applying this guidance and believes that it has transactions that may fall under the scope of this guidance.

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share (in thousands, except per share data): Three Months Ended March 31 2021 2020 Numerator: Net loss $ (9,435 ) $ (50,703 ) Net loss allocated to stockholders of the Company $ (9,259 ) $ (50,190 ) Denominator: Weighted-average shares of common stock outstanding used in computing net loss per share, basic and diluted 53,744 29,812 Net loss per share: Basic and diluted $ (0.17 ) $ (1.68 )
Outstanding Shares of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders	Due to the net loss, all the outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would have been antidilutive : March 31, 2021 March 31, 2020 Options to purchase common stock 2,532,184 2,730,791 Preferred stock - 660,000 Warrants for common stock 15,928,867 10,665,067 Total potential dilutive shares 18,461,051 14,055,858

Fair Value Measurements - (Tabl

Fair Value Measurements - (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Level 1, Level 2 and Level 3 Financial Assets and Liabilities	The following tables set forth the fair value of the Company’s Level 1, Level 2 and Level 3 financial assets and liabilities within the fair value hierarchy: Fair Value Measurements as of March 31, 2021 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates (GIC) $ — $ 65 $ — $ 65 Restricted cash 83 — — 83 Total assets $ 83 $ 65 $ — $ 148 Fair Value Measurements as of December 31, 2020 Quoted Prices in Active Markets using Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets Guaranteed Investment Certificates (GIC) $ — $ 64 $ — $ 64 Restricted cash 83 — — 83 Total assets $ 83 $ 64 $ — $ 147 Liabilities Contingent earn-out consideration — — 147 147 Total liabilities $ — $ — $ 147 $ 147
Schedule Aggregate Fair Values of Earn-out Liability	The following table provides a roll forward of the aggregate fair values of the earn-out liability for the three months ended March 31 Balance as of January 1, 2020 $ 655 Payments (799 ) Change in value 291 Balance as of December 31, 2020 147 Payments (147 ) Change in value - Balance as of March 31, 2021 $ -

Accounts Receivable (Tables)

Accounts Receivable (Tables)	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Summary of Accounts Receivables	A summary of the Company’s accounts receivables is presented below: March 31, 2021 December 31, 2020 Gross accounts receivable $ 88,060 $ 92,402 Unearned income (3,478 ) (3,728 ) Allowance for doubtful accounts (17,694 ) (18,490 ) $ 66,888 $ 70,184 Reported as: Current trade receivables $ 51,070 $ 52,764 Current unearned interest income (2,444 ) (1,950 ) Long-term trade receivables 19,296 21,148 Long-term unearned interest income (1,034 ) (1,778 ) $ 66,888 $ 70,184
Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts	The following are the contractual commitments, net of allowance for doubtful accounts, to be received by the Company over the next 5 years: March 31, Total 2021 2022 2023 2024 2025 Current financing receivables, net of allowance of $6,588 $ 26,609 $ 26,609 $ — $ — $ — $ — Long-term financing receivables, net of allowance of $4,629 19,295 — 14,380 4,837 78 — $ 45,904 $ 26,609 $ 14,380 $ 4,837 $ 78 $ —
Summary of Allowance for Doubtful Accounts	The allowance for doubtful accounts consisted of the following activity: Balance as of January 1, 2020 $ 10,494 Write-offs (6,536 ) Provision 15,212 Sale of subsidiaries (680 ) Balance as of December 31, 2020 18,490 Write-offs (1,902 ) Provision 1,106 Balance as of March 31, 2021 17,694

Select Balance Sheet and Stat_2

Select Balance Sheet and Statement of Operations Information (Tables)	3 Months Ended
	Mar. 31, 2021
Select Balance Sheet And Income Statement Information [Abstract]
Schedule of Inventory	Inventory March 31, 2021 December 31, 2020 Raw materials $ 1,908 $ 838 Work-in-progress 891 1,232 Finished goods 15,186 15,689 Total inventory $ 17,985 $ 17,759
Schedule of Property and Equipment, Net	Property Useful Lives (in years) March 31, 2021 December 31, 2020 Lab equipment tooling and molds 4 - 10 $ 8,075 $ 8,053 Office furniture and equipment 6 - 10 1,716 1,760 Leasehold improvements up to 10 1,791 1,838 Computers and software 3 1,813 1,815 Vehicles 5 - 7 19 12 Total property and equipment 13,414 13,478 Less: Accumulated depreciation (10,282 ) (9,939 ) Total property and equipment, net $ 3,132 $ 3,539
Schedule of Other Current Assets	Other Current Assets March 31, 2021 December 31, 2020 Government remittances (1) $ 1,049 $ 1,009 Consideration receivable from sales of subsidiaries 2,293 2,580 Deferred financing costs 381 1,063 Sundry assets and miscellaneous 687 1,022 Total other current assets $ 4,410 $ 5,674 (1) Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes.
Schedule of Accrued Expenses and Other Current Liabilities	March 31, 2021 December 31, 2020 Payroll and related expense $ 1,513 $ 1,312 Accrued expenses 6,240 8,582 Commission accrual 2,265 2,827 Sales and consumption taxes 6,312 7,532 Total accrued expenses and other current liabilities $ 16,330 $ 20,253
Schedule of Change in Warranty Accrual	The following table provides the details of the change in the Company’s warranty accrual: March 31, 2021 December 31, 2020 Balance as of the beginning of the period $ 1,639 $ 1,977 Warranties issued during the period 295 761 Warranty costs incurred during the period (241 ) (1,099 ) Balance at the end of the period $ 1,693 $ 1,639 Current 1,222 1,106 Long-term 471 533 Total $ 1,693 $ 1,639
Schedule of Finance Expenses	Three Months Ended March 31 2021 2020 Interest expense $ 1,138 $ 2,108 Accretion on long-term debt and amortization of fees 747 146 Total finance expenses $ 1,885 $ 2,254

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Net of Accumulated Amortization and Goodwill	Intangible assets net of accumulated amortization and goodwill were as follows: At March 31, 2021 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (265 ) $ 1,135 Brand 2,500 (604 ) 1,896 Technology 16,900 (3,980 ) 12,920 Supplier agreement 3,000 (941 ) 2,059 Total intangible assets $ 23,800 $ (5,790 ) $ 18,010 At December 31, 2020 Gross Amount Accumulated Amortization Net Amount Customer relationships $ 1,400 $ (242 ) $ 1,158 Brand 2,500 (540 ) 1,960 Technology 16,900 (3,286 ) 13,614 Supplier agreement 3,000 (867 ) 2,133 Total intangible assets $ 23,800 $ (4,935 ) $ 18,865
Schedule of Estimated Amortization Expense	Estimated amortization expense for the next five fiscal years and all years thereafter are as follows: April 1, 2021 to December 31, 2021 $ 2,618 2022 3,473 2023 3,473 2024 3,473 2025 3,004 Thereafter 1,969 Total $ 18,010

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Summary of Future Minimum Lease Payments and Purchase and Service Commitments with Manufacturers and Service Providers	Aggregate future minimum lease payments and purchase and service commitments with manufacturers and service providers as of March 31, 2021 are as follows: Office Lease Purchase and Service Commitments Total April 1, 2021 to March 31, 2022 $ 1,145 $ 8,287 $ 9,432 2023 718 — 718 2024 333 — 333 2025 210 — 210 2026 210 — 210 Thereafter 1,024 — 1,024 Total $ 3,640 $ 8,287 $ 11,927

Main Street Term Loan (Tables)

Main Street Term Loan (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Instrument [Line Items]
Schedule Payments on Outstanding Borrowings	The scheduled payments on the outstanding borrowings as of March 31, 2021 are as follows: As of March 31, 2021 2021 $ 1,609 2022 2,136 2023 2,102 2024 1,606 2025 28,196 Total $ 35,649
MSLP Loan Agreement
Debt Instrument [Line Items]
Schedule Payments on Outstanding Borrowings	The scheduled payments on the outstanding borrowings as of March 31, 2021 are as follows: As of March 31, 2021 2021 $ - 2022 1,604 2023 9,339 2024 7,942 2025 38,416 Total $ 57,301

Madryn Long-term Debt and Con_2

Madryn Long-term Debt and Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule Payments on Outstanding Borrowings	The scheduled payments on the outstanding borrowings as of March 31, 2021 are as follows: As of March 31, 2021 2021 $ 1,609 2022 2,136 2023 2,102 2024 1,606 2025 28,196 Total $ 35,649

Common Stock Reserved For Iss_2

Common Stock Reserved For Issuance (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Common Stock Reserved for Issuance	The Company is required to reserve and keep available out of its authorized but unissued shares of common stock a number of shares sufficient to affect the exercise of all options granted and available for grant under the incentive plans and warrants to purchase common stock. March 31, 2021 December 31, 2020 Outstanding common stock warrants 15,928,867 16,290,067 Outstanding stock options 5,899,296 4,433,392 Shares reserved for future option grants 781,227 262,622 Shares reserved for Lincoln Park 5,222,867 5,222,867 Shares reserved for Madryn Noteholders 8,213,880 8,213,880 Total common stock reserved for issuance 36,046,137 34,422,828

Stockholders Equity (Tables)

Stockholders Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Summary of Recognized Stock-based Compensation Expense for Employees and Non-employees	The Company recognized stock-based compensation for its employees and non-employees in the accompanying unaudited condensed consolidated statements of operations as follows: Three Months Ended March 31 2021 2020 Cost of sales $ 7 $ 6 Selling and marketing 217 192 General and administrative 264 299 Research and development 20 20 Total stock-based compensation $ 508 $ 517
Assumptions used in Fair Value of Option Estimated at Date of Grant using Black-Scholes-Merton Option Pricing Formula	The fair value of each option is estimated at the date of grant using the Black-Scholes option pricing formula with the following assumptions : Three Months Ended March 31 2021 2020 Expected term (in years) 6.01 5.00-6.64 Risk-free interest rate 1.09 % 0.57-1.50 % Expected volatility 44.80 % 43.00 % Expected dividend rate 0 % 0 %
Summary of Stock Option Activity	The following table summarizes stock option activity under the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price per Share, $ Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding – January 1, 2021 4,433,392 $ 4.59 6.20 $ 247 Options granted 1,857,000 2.37 - Options exercised (157,304 ) 2.39 157 Options forfeited/cancelled (233,792 ) 4.49 - Outstanding - March 31, 2021 5,899,296 $ 3.98 7.37 $ 502 Exercisable – March 31, 2021 2,532,184 $ 4.70 4.60 $ 493 Expected to vest – after March 31, 2021 3,367,112 $ 3.44 9.46 $ -
Summary of Information about Stock Options Outstanding and Exercisable	The following tables summarize information about stock options outstanding and exercisable at March 31, 2021: Options Outstanding Options Exercisable Exercise Price Range Number Weighted average remaining contractual term (years) Weighted average Exercise Price Options exercisable Weighted average remaining contractual term (years) Weighted average Exercise Price $0.15 - $3.64 4,405,983 7.72 $ 2.81 1,498,108 4.00 $ 2.86 $4.26 - $7.95 1,437,306 6.34 6.78 991,451 5.44 6.54 $12.45 - $26.10 34,442 7.44 18.49 21,451 7.30 18.89 $27.00 - $33.00 12,998 3.60 27.99 12,962 3.59 27.98 $36.00 - $94.65 8,567 6.30 45.74 8,212 6.26 45.31 5,899,296 7.37 $ 3.98 2,532,184 4.60 $ 4.70

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Income Tax Expense	The Company generated a loss and recognized $ nil A reconciliation of income tax expense is as follows: Three Months Ended March 31 2021 2020 Loss before income taxes $ (9,435 ) $ (50,114 ) Theoretical tax benefit at the statutory rate (21.0% in 2021, 24.1% in 2020) (1,981 ) (12,077 ) Differences in jurisdictional tax rates (354 ) (172 ) Losses utilization — (101 ) Valuation allowance 1,984 5,362 Non-deductible expenses 334 7,577 Other 17 — Total income tax expense — 589 Net loss $ (9,435 ) $ (50,703 )

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Revenue by Geographic Area	Revenue by geographic location, which is based on the product shipped to location, is summarized as follows: Three Months Ended March 31 2021 2020 United States $ 10,877 $ 5,640 International 11,720 8,868 Total revenue $ 22,597 $ 14,508
Schedule of Revenue by Type	The following table presents revenue by type: Three Months Ended March 31 2021 2020 Lease revenue $ 8,537 $ 6,813 System revenue 9,810 3,498 Product revenue 3,055 2,717 Service revenue 1,195 1,480 Total revenue $ 22,597 $ 14,508

Nature of Operations - Addition

Nature of Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 22, 2020	Feb. 28, 2021	Mar. 31, 2021	Dec. 31, 2020
Nature Of Operations [Line Items]
Accumulated deficit			$ 166,651	$ 157,392
Common stock, par value			$ 0.0001	$ 0.0001
Exercises of 2020 December Public Offering Warrants			$ 903
December 2020 Public Offering
Nature Of Operations [Line Items]
Common stock, shares issued	11,250,000
Combined offering price per share	$ 2
December 2020 Public Offering | Common Stock
Nature Of Operations [Line Items]
Common stock, par value	0.0001
December 2020 Public Offering Warrants
Nature Of Operations [Line Items]
Warrants to purchase shares of common stock		361,200
Exercise price of warrants	$ 2.50	$ 2.50
Warrants expiry period	5 years
Warrants exercisable period			The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately.
Gross proceeds from stock issuance	$ 22,500
Exercises of 2020 December Public Offering Warrants		$ 903
Maximum | December 2020 Public Offering Warrants
Nature Of Operations [Line Items]
Warrants to purchase shares of common stock	5,625,000

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Numerator:
Net loss	$ (9,435)	$ (50,703)
Net loss allocated to stockholders of the Company	$ (9,259)	$ (50,190)
Weighted-average number of shares used in per share calculation:
Weighted-average shares of common stock outstanding used in computing net loss per share, basic and diluted	53,744	29,812
Net loss per share:
Basic and diluted	$ (0.17)	$ (1.68)

Net Loss Per Share - Outstandin

Net Loss Per Share - Outstanding Shares of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	18,461,051	14,055,858
Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares		660,000
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	2,532,184	2,730,791
Warrants for Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	15,928,867	10,665,067

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Level 1, Level 2 and Level 3 Financial Assets and Liabilities - (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	$ 148	$ 147
Total liabilities		147
Quoted Prices in Active Markets using Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	83	83
Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	65	64
Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total liabilities		147
Guaranteed Investment Certificates
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	65	64
Guaranteed Investment Certificates | Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	65	64
Restricted Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	83	83
Restricted Cash | Quoted Prices in Active Markets using Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	$ 83	83
Contingent Earn-out Consideration
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total liabilities		147
Contingent Earn-out Consideration | Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total liabilities		$ 147

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule Aggregate Fair Values of Earn-out Liability - (Details) - Level 3 - Contingent Earn-out Consideration - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 147	$ 655
Payments	$ (147)	(799)
Change in value		291
Ending balance		$ 147

Accounts Receivable - Additiona

Accounts Receivable - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Notes and Loans Receivable [Line Items]
Sales-type leases term of lease	36 months
Allowance for doubtful accounts	$ 17,694	$ 18,490	$ 10,494
Accounts Receivable | Customer Concentration Risk
Accounts Notes and Loans Receivable [Line Items]
Allowance for doubtful accounts	17,694	18,490
Trade Receivables and Long-term Receivables
Accounts Notes and Loans Receivable [Line Items]
Financing receivables, consisting of sales-type leases	$ 45,904	$ 49,096

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Notes and Loans Receivable [Line Items]
Gross accounts receivable	$ 88,060	$ 92,402
Unearned income	(3,478)	(3,728)
Allowance for doubtful accounts	(17,694)	(18,490)	$ (10,494)
Net accounts receivable	66,888	70,184
Current trade receivables	51,070	52,764
Current unearned interest income	(2,444)	(1,950)
Long-term receivables	19,296	21,148
Long-term unearned interest income	(1,034)	(1,778)
Trade Accounts Receivable
Accounts Notes and Loans Receivable [Line Items]
Current trade receivables	51,070	52,764
Long-term receivables	$ 19,296	$ 21,148

Accounts Receivable - Schedule

Accounts Receivable - Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts (Details) $ in Thousands	Mar. 31, 2021USD ($)
Accounts Notes and Loans Receivable [Line Items]
Total financing receivables	$ 45,904
2021	26,609
2022	14,380
2023	4,837
2024	78
Current financing receivables, net of allowance of $6,588
Accounts Notes and Loans Receivable [Line Items]
Total financing receivables	26,609
2021	26,609
Long-term financing receivables, net of allowance of $4,629
Accounts Notes and Loans Receivable [Line Items]
Total financing receivables	19,295
2022	14,380
2023	4,837
2024	$ 78

Accounts Receivable - Schedul_2

Accounts Receivable - Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts (Parenthetical) (Details) $ in Thousands	Mar. 31, 2021USD ($)
Receivables [Abstract]
Allowance for current financing receivables	$ 6,588
Allowance for long-term financing receivables	$ 4,629

Accounts Receivable - Summary_2

Accounts Receivable - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Receivables [Abstract]
Balance at beginning of period	$ 18,490	$ 10,494	$ 10,494
Write-offs	(1,902)		(6,536)
Provision	1,106	$ 1,547	15,212
Sale of subsidiaries			(680)
Balance at end of period	$ 17,694		$ 18,490

Select Balance Sheet and Stat_3

Select Balance Sheet and Statement of Operations Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,908	$ 838
Work-in-progress	891	1,232
Finished goods	15,186	15,689
Total inventory	$ 17,985	$ 17,759

Select Balance Sheet and Stat_4

Select Balance Sheet and Statement of Operations Information - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Select Balance Sheet And Statement Of Operations Information [Abstract]
Cost of goods sold	$ 6,020	$ 3,600
Provision for inventory obsolescence	1,434		$ 1,208
Depreciation expense	$ 448	$ 377

Select Balance Sheet and Stat_5

Select Balance Sheet and Statement of Operations Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Lab equipment tooling and molds	$ 8,075	$ 8,053
Office furniture and equipment	1,716	1,760
Leasehold improvements	1,791	1,838
Computers and software	1,813	1,815
Vehicles	19	12
Total property and equipment	13,414	13,478
Less: Accumulated depreciation	(10,282)	(9,939)
Total property and equipment, net	$ 3,132	$ 3,539
Lab Equipment Tooling and Molds | Minimum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P4Y
Lab Equipment Tooling and Molds | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P10Y
Office Furniture and Equipment | Minimum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P6Y
Office Furniture and Equipment | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P10Y
Leasehold Improvements | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P10Y
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P3Y
Vehicles | Minimum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P5Y
Vehicles | Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P7Y

Select Balance Sheet and Stat_6

Select Balance Sheet and Statement of Operations Information - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands		Mar. 31, 2021	Dec. 31, 2020
Other Assets [Abstract]
Government remittances	[1]	$ 1,049	$ 1,009
Consideration receivable from sales of subsidiaries		2,293	2,580
Deferred financing costs		381	1,063
Sundry assets and miscellaneous		687	1,022
Total other current assets		$ 4,410	$ 5,674
[1]	Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes.

Select Balance Sheet and Stat_7

Select Balance Sheet and Statement of Operations Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Payroll and related expense	$ 1,513	$ 1,312
Accrued expenses	6,240	8,582
Commission accrual	2,265	2,827
Sales and consumption taxes	6,312	7,532
Total accrued expenses and other current liabilities	$ 16,330	$ 20,253

Select Balance Sheet and Stat_8

Select Balance Sheet and Statement of Operations Information - Schedule of Change in Warranty Accrual (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Product Warranty Accrual Balance Sheet Classification [Abstract]
Warranty accrual, Balance as of the beginning of the period	$ 1,639	$ 1,977
Warranties issued during the period	295	761
Warranty costs incurred during the period	(241)	(1,099)
Warranty accrual, Balance at the end of the period	1,693	1,639
Current	1,222	1,106
Long-term	$ 471	$ 533

Select Balance Sheet and Stat_9

Select Balance Sheet and Statement of Operations Information - Schedule of Finance Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Interest And Debt Expense [Abstract]
Interest expense	$ 1,138	$ 2,108
Accretion on long-term debt and amortization of fees	747	146
Total finance expenses	$ 1,885	$ 2,254

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets Net of Accumulated Amortization and Goodwill (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Goodwill And Intangible Assets [Line Items]
Gross Amount	$ 23,800	$ 23,800
Accumulated Amortization	(5,790)	(4,935)
Net Amount	18,010	18,865
Customer Relationships
Goodwill And Intangible Assets [Line Items]
Gross Amount	1,400	1,400
Accumulated Amortization	(265)	(242)
Net Amount	1,135	1,158
Brand Name
Goodwill And Intangible Assets [Line Items]
Gross Amount	2,500	2,500
Accumulated Amortization	(604)	(540)
Net Amount	1,896	1,960
Technology
Goodwill And Intangible Assets [Line Items]
Gross Amount	16,900	16,900
Accumulated Amortization	(3,980)	(3,286)
Net Amount	12,920	13,614
Supplier Agreement
Goodwill And Intangible Assets [Line Items]
Gross Amount	3,000	3,000
Accumulated Amortization	(941)	(867)
Net Amount	$ 2,059	$ 2,133

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
April 1, 2021 to December 31, 2021	$ 2,618
2022	3,473
2023	3,473
2024	3,473
2025	3,004
Thereafter	1,969
Net Amount	$ 18,010	$ 18,865

Commitments and Contingencies -

Commitments and Contingencies - Summary of Future Minimum Lease Payments and Purchase and Service Commitments with Manufacturers and Service Providers (Details) $ in Thousands	Mar. 31, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
April 1, 2021 to March 31, 2022, Office Lease	$ 1,145
2023, Office Lease	718
2024, Office Lease	333
2025, Office Lease	210
2026, Office Lease	210
Thereafter, Office Lease	1,024
Total, Office Lease	3,640
April 1, 2021 to March 31, 2022, Purchase and Service Commitments	8,287
Total, Purchase and Service Commitments	8,287
Contractual Obligation, Fiscal Year Maturity [Abstract]
April 1, 2021 to March 31, 2022	9,432
2023	718
2024	333
2025	210
2026	210
Thereafter	1,024
Total	$ 11,927

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details) ¥ in Thousands, $ in Thousands	Mar. 04, 2021USD ($)	Mar. 04, 2021CNY (¥)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Jun. 11, 2019Complaint
Commitment And Contingencies [Line Items]
Rent expense			$ 571	$ 570
Purchase obligation			8,287
Number of complaints filed | Complaint					4
Xuhui MSA Market Regulation
Commitment And Contingencies [Line Items]
Penalty amount	$ 150	¥ 976
Contract Manufacturers
Commitment And Contingencies [Line Items]
Purchase obligation			6,585
Open Purchase Order
Commitment And Contingencies [Line Items]
Purchase obligation			$ 7,019
Open purchase cancellation period			90 days
Percentage of open purchase order			15.00%

Main Street Term Loan - Additio

Main Street Term Loan - Additional Information (Details) - MSLP Loan Agreement - USD ($) $ in Thousands	Dec. 08, 2024	Dec. 08, 2023	Dec. 08, 2020	Mar. 31, 2021
Debt Instrument [Line Items]
Debt instrument face amount			$ 50,000
Debt instrument term			5 years
Debt instrument, description of variable rate basis			30-day LIBOR plus 3%.
Debt instrument basis spread on variable rate			3.00%
Debt instrument, maturity date				Dec. 8, 2025
Scenario Forecast
Debt Instrument [Line Items]
Debt instrument percentage of outstanding principal to be paid with accrued unpaid interest	15.00%	15.00%

Main Street Term Loan - Schedul

Main Street Term Loan - Schedule Payments on Outstanding Borrowings (Details) $ in Thousands	Mar. 31, 2021USD ($)
Debt Instrument [Line Items]
2021	$ 1,609
2022	2,136
2023	2,102
2024	1,606
2025	28,196
Total	35,649
MSLP Loan Agreement
Debt Instrument [Line Items]
2022	1,604
2023	9,339
2024	7,942
2025	38,416
Total	$ 57,301

Madryn Long-term Debt and Con_3

Madryn Long-term Debt and Convertible Notes - Additional Information (Details) - USD ($)	Dec. 09, 2020	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001
Repayments of long-term debt		$ 0
Madryn Credit Agreement
Debt Instrument [Line Items]
Repayments of debt	$ 42,500,000
Credit agreement termination date		Dec. 9, 2020
Secured Subordinated Convertible Notes
Debt Instrument [Line Items]
Increase in applicate interest rate		4.00%
Debt instrument, interest rate terms		Interest is payable quarterly in arrears on the last business day of each calendar quarter of each year after the original issuance date, beginning on December 31, 2020.
Issuance date		Dec. 31, 2020
Debt instrument, maturity date		Dec. 9, 2025
Debt instrument termination description		The security interests and liens granted to the Madryn Noteholders under the Madryn Security Agreement will terminate upon the earlier of (i) an assignment of the Notes (other than to an affiliate of the Madryn Noteholders) pursuant to the terms of the Exchange Agreement and (ii) the first date on which the outstanding principal amount of the Notes is less than $10,000.
Debt instrument term		5 years
Common stock, par value		$ 0.0001
Initial conversion price		$ 3.25
Interest expense		$ 527,000
Secured Subordinated Convertible Notes | Maximum
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 10,000,000
Secured Subordinated Convertible Notes | Original Issuance of Notes to Third Anniversary Date
Debt Instrument [Line Items]
Accrue interest rate		8.00%
Secured Subordinated Convertible Notes | Original Issuance and Thereafter
Debt Instrument [Line Items]
Accrue interest rate		6.00%
Secured Subordinated Convertible Notes | Third Anniversary
Debt Instrument [Line Items]
Decrease in interest rate		6.00%
Secured Subordinated Convertible Notes | Madryn Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount	$ 26,695,000

Madryn Long-term Debt and Con_4

Madryn Long-term Debt and Convertible Notes - Schedule Payments on Outstanding Borrowings (Details) $ in Thousands	Mar. 31, 2021USD ($)
Debt Disclosure [Abstract]
2021	$ 1,609
2022	2,136
2023	2,102
2024	1,606
2025	28,196
Total	$ 35,649

Credit Facility - Additional In

Credit Facility - Additional Information (Details) - Revolving Credit Facility - City National Bank of Florida	3 Months Ended
	Mar. 31, 2021USD ($)
Line Of Credit Facility [Line Items]
Revolving credit facility, maximum outstanding amount	$ 10,000,000
Line of credit facility cash held in deposit account period	1 year
Escrow deposit	$ 20,000,000
Line of credit facility minimum deposit required	3,000,000
Loan fee paid	$ 1,000,000
Installment One
Line Of Credit Facility [Line Items]
Line of credit facility loan fee payment date	January 25
Installment Two
Line Of Credit Facility [Line Items]
Line of credit facility loan fee payment date	February 25
Installment Three
Line Of Credit Facility [Line Items]
Line of credit facility loan fee payment date	March 25, 2021
Minimum
Line Of Credit Facility [Line Items]
Line of credit facility cash held in deposit account	$ 23,000,000
Line of credit facility cash held in deposit account after one year	$ 3,000,000

Government Assistance Programs

Government Assistance Programs - Additional Information (Details) $ in Thousands	Apr. 29, 2020USD ($)	Apr. 20, 2020USD ($)	Mar. 31, 2021USD ($)Loan	Dec. 31, 2020USD ($)
Government Assistance Programs [Line Items]
Debt outstanding balance			$ 35,649
Government Assistance Programs | Paycheck Protection Program | Venus Concept USA Inc.
Government Assistance Programs [Line Items]
Number of small business loans | Loan			2
Government Assistance Programs | Subsidiaries | Canada Emergency Wage Subsidy
Government Assistance Programs [Line Items]
Government subsidies received			$ 1,117
Government Assistance Programs | Small Business Loans | Paycheck Protection Program | Venus Concept USA Inc.
Government Assistance Programs [Line Items]
Fund amount received			4,048
Government Assistance Programs | Venus Concept PPP Loan | Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt instrument, principal amount	$ 1,665
Debt instrument, interest rate, stated percentage	1.00%
Debt instrument, term of maturity	2 years
Government Assistance Programs | Venus Concept PPP Loan | Paycheck Protection Program | Long-Term Liabilities
Government Assistance Programs [Line Items]
Debt instrument, principal amount			1,086
Government Assistance Programs | Venus USA PPP Loan | Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt instrument, principal amount		$ 2,383
Government Assistance Programs | Venus USA PPP Loan | Paycheck Protection Program | Long-Term Liabilities
Government Assistance Programs [Line Items]
Debt instrument, principal amount			1,689
Government Assistance Programs | Venus Concept USA Inc. | Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt forgiveness description		U.S. Small Business Administration (the “SBA”) has decided, in consultation with the Department of the Treasury, that it will review all loans in excess of $2,000 following the lender’s submission of the borrower’s loan forgiveness application.
Government Assistance Programs | PPP Loans | Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt outstanding balance			$ 4,151	$ 4,110

Common Stock Reserved for Iss_3

Common Stock Reserved for Issuance - Schedule of Common Stock Reserved for Issuance (Details) - shares	Mar. 31, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Outstanding stock options	5,899,296	4,433,392
Total common stock reserved for issuance	36,046,137	34,422,828
Common Stock
Class Of Stock [Line Items]
Outstanding common stock warrants	15,928,867	16,290,067
Option
Class Of Stock [Line Items]
Shares reserved for future grants	781,227	262,622
Lincoln Park
Class Of Stock [Line Items]
Shares reserved for future grants	5,222,867	5,222,867
Madryn Noteholders
Class Of Stock [Line Items]
Shares reserved for future grants	8,213,880	8,213,880

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Details) - USD ($)	Dec. 22, 2020	Feb. 28, 2021	Dec. 31, 2020	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 16, 2020	Oct. 04, 2019
Class Of Stock [Line Items]
Common stock voting rights					one vote
Net proceeds from private placement				$ 20,300,000		$ 20,300,000
Beneficial conversion feature				3,564,000		$ 3,564,000
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares issued			53,551,126		54,069,630
Exercises of 2020 December Public Offering Warrants					$ 903,000
Common stock reserved for issuance			34,422,828		36,046,137
Expected dividend					$ 0
Total intrinsic value of options exercised					$ 157,000
Weighted-average grant date fair value of options granted					$ 2.37	$ 7.515
2010 Share Option Plan
Class Of Stock [Line Items]
Stock option, vesting period					7 years
Stock option, vesting period extension					10 years
Common stock reserved for issuance			138,275		93,439
2019 Incentive Award Plan
Class Of Stock [Line Items]
Common stock reserved for issuance			124,347		687,788			450,000
Percentage of stock outstanding					4.00%
2020 Private Placement Warrants
Class Of Stock [Line Items]
Net proceeds from private placement				$ 4,621,000
December 2020 Public Offering Warrants and Common Stock
Class Of Stock [Line Items]
Net proceeds from shares issuance			$ 20,476,000
December 2020 Public Offering Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		361,200
Exercise price of warrants	$ 2.50	$ 2.50
Warrants expiry period	5 years
Warrants exercisable period					The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately.
Net proceeds from shares issuance			$ 2,648,000
Exercises of 2020 December Public Offering Warrants		$ 903,000
December 2020 Public Offering Warrants | Maximum
Class Of Stock [Line Items]
Warrants to purchase shares of common stock	5,625,000
Investor | 2020 Private Placement Warrants
Class Of Stock [Line Items]
Exercise price of warrants				$ 3.50		$ 3.50
Warrants expiry period				5 years
Warrants exercisable period					beginning 181 days after their issue date
Investor | 2020 Private Placement Warrants | Maximum
Class Of Stock [Line Items]
Warrants to purchase shares of common stock				6,675,000		6,675,000
Investor | December 2020 Public Offering Warrants and Common Stock
Class Of Stock [Line Items]
Exercise price of warrants			$ 2.50
Warrants expiry period			5 years
Warrants exercisable period					The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately.
Common stock, shares issued			11,250,000
Investor | December 2020 Public Offering Warrants and Common Stock | Maximum
Class Of Stock [Line Items]
Warrants to purchase shares of common stock			5,625,000
Investor | December 2020 Public Offering Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		361,200
Exercise price of warrants		$ 2.50
Exercises of 2020 December Public Offering Warrants		$ 903,000
Common Stock
Class Of Stock [Line Items]
Net proceeds from private placement				$ 4,052,000
Conversion of Preferred Stock Series A, shares							6,600,000
Common Stock | 2020 Private Placement Warrants
Class Of Stock [Line Items]
Common stock, par value				$ 0.0001		$ 0.0001
Common Stock | December 2020 Public Offering Warrants and Common Stock
Class Of Stock [Line Items]
Common stock, par value			$ 0.0001
Net proceeds from shares issuance			$ 17,828,000
Series A Preferred Shares
Class Of Stock [Line Items]
Net proceeds from private placement				$ 8,063,000
Conversion of Preferred Stock Series A, shares							660,000
Series A Preferred Shares | 2020 Private Placement Warrants
Class Of Stock [Line Items]
Preferred stock, par value				$ 0.0001		$ 0.0001

Stockholders Equity - Summary o

Stockholders Equity - Summary of Recognized Stock-based Compensation Expense for Employees and Non-employees (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 508	$ 517
Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	508	517
Cost of Sales | Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	7	6
Selling and Marketing | Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	217	192
General and Administrative | Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	264	299
Research and Development | Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 20	$ 20

Stockholders Equity - Assumptio

Stockholders Equity - Assumptions used in Fair Value of Option Estimated at Date of Grant using Black-Scholes Option Pricing Formula (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 3 days
Risk-free interest rate	1.09%
Expected volatility	44.80%	43.00%
Expected dividend rate	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		5 years
Risk-free interest rate		0.57%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 7 months 20 days
Risk-free interest rate		1.50%

Stockholders Equity - Summary_2

Stockholders Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Number of Shares, Outstanding, Beginning Balance	4,433,392
Number of Shares, Options granted	1,857,000
Number of Shares, Options exercised	(157,304)
Number of Shares, Options forfeited/cancelled	(233,792)
Number of Shares, Outstanding, Ending Balance	5,899,296	4,433,392
Number of Shares, Exercisable	2,532,184
Number of Shares, Expected to vest	3,367,112
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 4.59
Weighted-Average Exercise Price Per Share, Options granted	2.37
Weighted-Average Exercise Price Per Share, Options exercised	2.39
Weighted-Average Exercise Price Per Share, Options forfeited/cancelled	4.49
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	3.98	$ 4.59
Weighted-Average Exercise Price Per Share, Exercisable	4.70
Weighted-Average Exercise Price Per Share, Expected to vest	$ 3.44
Weighted-Average Remaining Contractual Term, Outstanding	7 years 4 months 13 days	6 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Exercisable	4 years 7 months 6 days
Weighted-Average Remaining Contractual Term, Expected to vest	9 years 5 months 16 days
Aggregate Intrinsic Value, Outstanding	$ 502	$ 247
Aggregate Intrinsic Value, Exercisable	$ 493

Stockholders Equity - Summary_3

Stockholders Equity - Summary of Information about Stock Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding, Number | shares	5,899,296
Options Outstanding, Weighted average remaining contractual term (years)	7 years 4 months 13 days
Options Outstanding, Weighted average Exercise Price	$ 3.98
Options Exercisable | shares	2,532,184
Options Exercisable, Weighted average remaining contractual term (years)	4 years 7 months 6 days
Options Exercisable, Weighted average Exercise Price	$ 4.70
$0.15 - $3.64
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	0.15
Exercise Price Range (Upper limit)	$ 3.64
Options Outstanding, Number | shares	4,405,983
Options Outstanding, Weighted average remaining contractual term (years)	7 years 8 months 19 days
Options Outstanding, Weighted average Exercise Price	$ 2.81
Options Exercisable | shares	1,498,108
Options Exercisable, Weighted average remaining contractual term (years)	4 years
Options Exercisable, Weighted average Exercise Price	$ 2.86
$4.26 - $7.95
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	4.26
Exercise Price Range (Upper limit)	$ 7.95
Options Outstanding, Number | shares	1,437,306
Options Outstanding, Weighted average remaining contractual term (years)	6 years 4 months 2 days
Options Outstanding, Weighted average Exercise Price	$ 6.78
Options Exercisable | shares	991,451
Options Exercisable, Weighted average remaining contractual term (years)	5 years 5 months 9 days
Options Exercisable, Weighted average Exercise Price	$ 6.54
$12.45 - $26.10
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	12.45
Exercise Price Range (Upper limit)	$ 26.10
Options Outstanding, Number | shares	34,442
Options Outstanding, Weighted average remaining contractual term (years)	7 years 5 months 9 days
Options Outstanding, Weighted average Exercise Price	$ 18.49
Options Exercisable | shares	21,451
Options Exercisable, Weighted average remaining contractual term (years)	7 years 3 months 19 days
Options Exercisable, Weighted average Exercise Price	$ 18.89
$27.00 - $33.00
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	27
Exercise Price Range (Upper limit)	$ 33
Options Outstanding, Number | shares	12,998
Options Outstanding, Weighted average remaining contractual term (years)	3 years 7 months 6 days
Options Outstanding, Weighted average Exercise Price	$ 27.99
Options Exercisable | shares	12,962
Options Exercisable, Weighted average remaining contractual term (years)	3 years 7 months 2 days
Options Exercisable, Weighted average Exercise Price	$ 27.98
$36.00 - $94.65
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	36
Exercise Price Range (Upper limit)	$ 94.65
Options Outstanding, Number | shares	8,567
Options Outstanding, Weighted average remaining contractual term (years)	6 years 3 months 19 days
Options Outstanding, Weighted average Exercise Price	$ 45.74
Options Exercisable | shares	8,212
Options Exercisable, Weighted average remaining contractual term (years)	6 years 3 months 4 days
Options Exercisable, Weighted average Exercise Price	$ 45.31

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Tax (benefit) expense		$ 589

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Loss before income taxes	$ (9,435)	$ (50,114)
Theoretical tax benefit at the statutory rate (21.0% in 2021, 24.1% in 2020)	(1,981)	(12,077)
Differences in jurisdictional tax rates	(354)	(172)
Losses utilization		(101)
Valuation allowance	1,984	5,362
Non-deductible expenses	334	7,577
Other	17
Total income tax expense		589
Net loss	$ (9,435)	$ (50,703)

Income Taxes - Schedule of Re_2

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Parenthetical) (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Theoretical tax benefit, statutory rate	21.00%	24.10%

Segment and Geographic Inform_3

Segment and Geographic Information - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | Segment	1
Number of reportable segments | Segment	1
Lease Revenue
Segment Reporting Information [Line Items]
System sales with typical lease terms	36 months
System Revenue
Segment Reporting Information [Line Items]
Systems sales with payment terms	12 months
United States
Segment Reporting Information [Line Items]
Long-lived assets | $	$ 18,868	$ 19,828
Foreign
Segment Reporting Information [Line Items]
Long-lived assets | $	$ 2,274	$ 2,576

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 22,597	$ 14,508
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	10,877	5,640
Foreign
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 11,720	$ 8,868

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Revenue by Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	$ 22,597	$ 14,508
Lease Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	8,537	6,813
System Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	9,810	3,498
Product Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	3,055	2,717
Service Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	$ 1,195	$ 1,480

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Med Group Consult Ltd | Venus Concept Singapore Pte. Ltd
Related Party Transaction [Line Items]
Percentage of ownership interest in subsidiaries sold			55.00%
Senior Officer | TBC
Related Party Transaction [Line Items]
Percentage of ownership by senior officer in TBC	30.00%
Senior Officer | Venus Concept Singapore Pte. Ltd
Related Party Transaction [Line Items]
Percentage of ownership by senior officer	45.00%
TBC
Related Party Transaction [Line Items]
Products purchased	$ 15	$ 49
Venus Concept Singapore Pte. Ltd
Related Party Transaction [Line Items]
Products purchased	$ 65